Drug intelligence / Profile preview

tipifarnib

Development stage: Phase 3
Lead developer: Kura Oncology
Modality: Small Molecules
Administration: Oral

Overview

Tipifarnib is a farnesyltransferase inhibitor used in the treatment of various cancers, including acute myeloid leukemia (AML). It works by inhibiting the enzyme farnesyltransferase, which is involved in the prenylation of proteins like Ras, preventing them from binding to the cell membrane and thus inhibiting their activity. It is administered orally.

Brand names: Zarnestra
Other names: NSC-702818NSC702818NSC 702818

Targets

DNAJA1 (DnaJ homolog subfamily A member 1)FTase (Protein Farnesyltransferase)RHEB (GTP-binding protein Rheb)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on tipifarnib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tipifarnib.